Tag: Abbott

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Critical Care Drugs Market By 2030 Starting From Its 2026 Size?

The critical care drugs market size has shown robust expansion in recent years. It is projected to increase from $1.13 billion in 2025 to $1.2 billion in 2026, progressing at a compound annual growth rate (CAGR) of 6.4%. This historical growth can be linked to factors such as a rising incidence of critical illnesses, increasing ICU admissions, limited availability of advanced critical care drugs, developing hospital infrastructure, and the reliance on conventional sedatives and analgesics.

The critical care drugs market is projected to experience substantial expansion over the coming years. It is set to reach $1.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period is fueled by factors such as the development of innovative opioids and sedatives, the incorporation of AI-based monitoring and dosing instruments, the broadening of acute care protocols, escalating government efforts to enhance ICU capacity, and the growing uptake of precision critical care treatments. Key trends anticipated in the same period involve a heightened utilization of sophisticated sedatives and analgesics within ICU environments, the increased embrace of continuous monitoring and dose optimization solutions, an expansion in drugs for acute care and critical event management, the proliferation of protocol-driven drug delivery in operating theatres, and an intensified emphasis on ensuring safety and reducing adverse drug reactions in critical care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27266&type=smp

What Drivers Are Shaping The Future Growth Of The Critical Care Drugs Market?

An escalating count of surgical procedures is projected to drive the expansion of the critical care drugs market in the future. Surgical procedures encompass medical interventions where physicians perform operations to correct or address health conditions such as injuries or illnesses. The increment in these surgical procedures can be attributed to the increasing prevalence of chronic diseases that necessitate operative treatment. Critical care drugs are deployed in surgical settings to manage pain, stabilize vital functions, avert infections, and facilitate recovery both during and following an operation. For instance, in May 2025, the Australian Institute of Health and Welfare, an Australia-based government agency, stated that during 2023–24, approximately 778,500 patients were admitted for surgery from public hospital waiting lists, representing a 5.8% rise when compared to 2022–23. This ongoing increase in surgical procedures is thus stimulating the growth of the critical care drugs market.

Which Segment Categories Define The Critical Care Drugs Market?

The critical care drugs market covered in this report is segmented –

1) By Drug Type: Opioids, Morphine, Pethidine, Naloxone, Fentanyl, Benzodiazepines, Diazepam, Midazolam, Lorazepum, Other Types

2) By Clinical Applications: Sepsis And Septic Shock, Acute Respiratory Distress Syndrome (ARDS), Acute Cardiovascular Events, Acute Kidney Injury, Traumatic Injuries

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Inhalation, Subcutaneous

4) By End User: Intensive Care Unit (ICU), Coronary Care Unit (CCU), Operation Theatres, Trauma Centers

Subsegments:

1) By Opioids: Codeine, Hydromorphone, Oxycodone, Tapentadol, Methadone

2) By Morphine: Immediate-Release Morphine, Extended-Release Morphine, Injectable Morphine, Oral Morphine Solutions

3) By Pethidine: Injectable Pethidine, Oral Pethidine, Pethidine Combinations

4) By Naloxone: Injectable Naloxone, Nasal Naloxone, Auto-injector Naloxone

5) By Fentanyl: Transdermal Patches, Injectable Fentanyl, Buccal Tablets, Sublingual Spray, Lozenges

6) By Benzodiazepines: Short-Acting Benzodiazepines, Intermediate-Acting Benzodiazepines, Long-Acting Benzodiazepines

7) By Diazepam: Oral Tablets, Injectable Diazepam, Rectal Gel, Oral Solution

8) By Midazolam: Injectable Midazolam, Nasal Spray, Buccal Formulation, Oral Syrup

9) By Lorazepam: Oral Tablets, Injectable Lorazepam, Oral Concentrate

10) By Other Types: Propofol, Ketamine, Dexmedetomidine, Etomidate, Clonidine

What Major Market Trends Are Driving Changes In The Critical Care Drugs Market?

Leading companies within the critical care drugs market are emphasizing strategic alliances to broaden their product offerings, improve research capacities, expedite market entry, and solidify their position in rapidly expanding therapeutic domains. These collaborations facilitate quicker research, development, and market access by leveraging collective expertise and shared resources. They empower pharmaceutical entities to cooperate with hospitals, research bodies, or biotechnology enterprises, thereby boosting drug innovation and the effectiveness of clinical trials. As an illustration, in March 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical firm, formed a partnership with US-based Pharmazz Inc. to introduce and commercialize Centhaquine, an inventive resuscitative medication for hypovolemic shock, in India, marketed under the brand Lyfaquin. This strategic agreement provides Dr. Reddy’s with sole marketing and distribution privileges in India and Nepal, while Pharmazz is set to receive initial payments and ongoing royalties. The alliance enhances Dr. Reddy’s critical care portfolio by integrating a new therapy, sanctioned by the Drugs Controller General of India (DCGI) for urgent situations, thereby reaffirming its dedication to providing crucial treatments for patients in critical condition.

Who Are The Top Companies Competing In The Critical Care Drugs Market?

Major companies operating in the critical care drugs market are Intas Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Ltd., Zydus Lifesciences Limited, Cargus Biopharma, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Mankind Pharma, Novalab Healthcare, Arlak Biotech Ltd., Pax Healthcare, SwissChem Healthcare, Iskon Remedies, Salvus Pharma, Fortune Labs, H&I Critical Care, Biofield Pharma.

Read the full critical care drugs market report here:

https://www.thebusinessresearchcompany.com/report/critical-care-drugs-global-market-report

Which Geographic Regions Are Influencing Demand In The Critical Care Drugs Market?

North America was the largest region in the critical care drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the critical care drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Critical Care Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27266&type=smp

Browse Through More Reports Similar to the Global Critical Care Drugs Market 2026, By The Business Research Company

Landscaping Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/landscaping-services-global-market-report

Architectural Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/architectural-services-global-market-report

Crop Production Market Report 2026

https://www.thebusinessresearchcompany.com/report/crop-production-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Critical Care Drugs Market By 2030 Starting From Its 2026 Size?

The critical care drugs market size has shown robust expansion in recent years. It is projected to increase from $1.13 billion in 2025 to $1.2 billion in 2026, progressing at a compound annual growth rate (CAGR) of 6.4%. This historical growth can be linked to factors such as a rising incidence of critical illnesses, increasing ICU admissions, limited availability of advanced critical care drugs, developing hospital infrastructure, and the reliance on conventional sedatives and analgesics.

The critical care drugs market is projected to experience substantial expansion over the coming years. It is set to reach $1.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period is fueled by factors such as the development of innovative opioids and sedatives, the incorporation of AI-based monitoring and dosing instruments, the broadening of acute care protocols, escalating government efforts to enhance ICU capacity, and the growing uptake of precision critical care treatments. Key trends anticipated in the same period involve a heightened utilization of sophisticated sedatives and analgesics within ICU environments, the increased embrace of continuous monitoring and dose optimization solutions, an expansion in drugs for acute care and critical event management, the proliferation of protocol-driven drug delivery in operating theatres, and an intensified emphasis on ensuring safety and reducing adverse drug reactions in critical care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27266&type=smp

What Drivers Are Shaping The Future Growth Of The Critical Care Drugs Market?

An escalating count of surgical procedures is projected to drive the expansion of the critical care drugs market in the future. Surgical procedures encompass medical interventions where physicians perform operations to correct or address health conditions such as injuries or illnesses. The increment in these surgical procedures can be attributed to the increasing prevalence of chronic diseases that necessitate operative treatment. Critical care drugs are deployed in surgical settings to manage pain, stabilize vital functions, avert infections, and facilitate recovery both during and following an operation. For instance, in May 2025, the Australian Institute of Health and Welfare, an Australia-based government agency, stated that during 2023–24, approximately 778,500 patients were admitted for surgery from public hospital waiting lists, representing a 5.8% rise when compared to 2022–23. This ongoing increase in surgical procedures is thus stimulating the growth of the critical care drugs market.

Which Segment Categories Define The Critical Care Drugs Market?

The critical care drugs market covered in this report is segmented –

1) By Drug Type: Opioids, Morphine, Pethidine, Naloxone, Fentanyl, Benzodiazepines, Diazepam, Midazolam, Lorazepum, Other Types

2) By Clinical Applications: Sepsis And Septic Shock, Acute Respiratory Distress Syndrome (ARDS), Acute Cardiovascular Events, Acute Kidney Injury, Traumatic Injuries

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Inhalation, Subcutaneous

4) By End User: Intensive Care Unit (ICU), Coronary Care Unit (CCU), Operation Theatres, Trauma Centers

Subsegments:

1) By Opioids: Codeine, Hydromorphone, Oxycodone, Tapentadol, Methadone

2) By Morphine: Immediate-Release Morphine, Extended-Release Morphine, Injectable Morphine, Oral Morphine Solutions

3) By Pethidine: Injectable Pethidine, Oral Pethidine, Pethidine Combinations

4) By Naloxone: Injectable Naloxone, Nasal Naloxone, Auto-injector Naloxone

5) By Fentanyl: Transdermal Patches, Injectable Fentanyl, Buccal Tablets, Sublingual Spray, Lozenges

6) By Benzodiazepines: Short-Acting Benzodiazepines, Intermediate-Acting Benzodiazepines, Long-Acting Benzodiazepines

7) By Diazepam: Oral Tablets, Injectable Diazepam, Rectal Gel, Oral Solution

8) By Midazolam: Injectable Midazolam, Nasal Spray, Buccal Formulation, Oral Syrup

9) By Lorazepam: Oral Tablets, Injectable Lorazepam, Oral Concentrate

10) By Other Types: Propofol, Ketamine, Dexmedetomidine, Etomidate, Clonidine

What Major Market Trends Are Driving Changes In The Critical Care Drugs Market?

Leading companies within the critical care drugs market are emphasizing strategic alliances to broaden their product offerings, improve research capacities, expedite market entry, and solidify their position in rapidly expanding therapeutic domains. These collaborations facilitate quicker research, development, and market access by leveraging collective expertise and shared resources. They empower pharmaceutical entities to cooperate with hospitals, research bodies, or biotechnology enterprises, thereby boosting drug innovation and the effectiveness of clinical trials. As an illustration, in March 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical firm, formed a partnership with US-based Pharmazz Inc. to introduce and commercialize Centhaquine, an inventive resuscitative medication for hypovolemic shock, in India, marketed under the brand Lyfaquin. This strategic agreement provides Dr. Reddy’s with sole marketing and distribution privileges in India and Nepal, while Pharmazz is set to receive initial payments and ongoing royalties. The alliance enhances Dr. Reddy’s critical care portfolio by integrating a new therapy, sanctioned by the Drugs Controller General of India (DCGI) for urgent situations, thereby reaffirming its dedication to providing crucial treatments for patients in critical condition.

Who Are The Top Companies Competing In The Critical Care Drugs Market?

Major companies operating in the critical care drugs market are Intas Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Ltd., Zydus Lifesciences Limited, Cargus Biopharma, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Mankind Pharma, Novalab Healthcare, Arlak Biotech Ltd., Pax Healthcare, SwissChem Healthcare, Iskon Remedies, Salvus Pharma, Fortune Labs, H&I Critical Care, Biofield Pharma.

Read the full critical care drugs market report here:

https://www.thebusinessresearchcompany.com/report/critical-care-drugs-global-market-report

Which Geographic Regions Are Influencing Demand In The Critical Care Drugs Market?

North America was the largest region in the critical care drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the critical care drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Critical Care Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27266&type=smp

Browse Through More Reports Similar to the Global Critical Care Drugs Market 2026, By The Business Research Company

Landscaping Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/landscaping-services-global-market-report

Architectural Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/architectural-services-global-market-report

Crop Production Market Report 2026

https://www.thebusinessresearchcompany.com/report/crop-production-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the critical care drugs market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Critical Care Drugs Market in 2030?

The critical care drugs market size has shown robust growth in recent years. It is expected to expand from $1.13 billion in 2025 to $1.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. This historical growth can be attributed to factors like the escalating incidence of critical illnesses, an increase in ICU admissions, the restricted availability of sophisticated critical care drugs, the development of hospital infrastructure, and a dependence on traditional sedatives and analgesics.

The critical care drugs market is anticipated to experience substantial growth in the coming years, reaching $1.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.1%. This expansion during the forecast period is propelled by factors such as the development of new opioids and sedatives, the integration of AI-based monitoring and dosing tools, the broadening of acute care protocols, escalating government efforts for ICU capacity enhancement, and a rise in the adoption of precision critical care therapies. Key trends for this period involve an increasing application of advanced sedatives and analgesics in ICU environments, growing adoption of continuous monitoring and dose optimization instruments, expansion in acute care and critical event management pharmaceuticals, wider implementation of protocol-based drug administration in operating theaters, and a heightened emphasis on patient safety and reducing adverse drug reactions in critical care settings.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27266&type=smp

What Drivers Are Influencing Production Trends In The Critical Care Drugs Market?

An anticipated increase in the number of surgical procedures is expected to propel the growth of the critical care drugs market going forward. These medical interventions involve doctors operating on the body to correct or address health issues like injuries or diseases. The frequency of surgical procedures is escalating due to the growing occurrence of chronic diseases that necessitate operative treatment. Critical care drugs are employed in surgical procedures to manage pain, stabilize vital functions, prevent infections, and support recovery during and following surgery. For instance, in May 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023–24, around 778,500 patients were admitted for surgery from public hospital waiting lists, which is a 5.8% rise compared to 2022–23. Therefore, the expanding volume of surgical procedures is driving the growth of the critical care drugs market.

Which Segment Groups Are Influencing The Critical Care Drugs Market?

The critical care drugs market covered in this report is segmented –

1) By Drug Type: Opioids, Morphine, Pethidine, Naloxone, Fentanyl, Benzodiazepines, Diazepam, Midazolam, Lorazepum, Other Types

2) By Clinical Applications: Sepsis And Septic Shock, Acute Respiratory Distress Syndrome (ARDS), Acute Cardiovascular Events, Acute Kidney Injury, Traumatic Injuries

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Inhalation, Subcutaneous

4) By End User: Intensive Care Unit (ICU), Coronary Care Unit (CCU), Operation Theatres, Trauma Centers

Subsegments:

1) By Opioids: Codeine, Hydromorphone, Oxycodone, Tapentadol, Methadone

2) By Morphine: Immediate-Release Morphine, Extended-Release Morphine, Injectable Morphine, Oral Morphine Solutions

3) By Pethidine: Injectable Pethidine, Oral Pethidine, Pethidine Combinations

4) By Naloxone: Injectable Naloxone, Nasal Naloxone, Auto-injector Naloxone

5) By Fentanyl: Transdermal Patches, Injectable Fentanyl, Buccal Tablets, Sublingual Spray, Lozenges

6) By Benzodiazepines: Short-Acting Benzodiazepines, Intermediate-Acting Benzodiazepines, Long-Acting Benzodiazepines

7) By Diazepam: Oral Tablets, Injectable Diazepam, Rectal Gel, Oral Solution

8) By Midazolam: Injectable Midazolam, Nasal Spray, Buccal Formulation, Oral Syrup

9) By Lorazepam: Oral Tablets, Injectable Lorazepam, Oral Concentrate

10) By Other Types: Propofol, Ketamine, Dexmedetomidine, Etomidate, Clonidine

How Are Emerging Trends Affecting The Progression Of The Critical Care Drugs Market?

Key players in the critical care drugs market are concentrating on strategic alliances to expand their product pipelines, enhance research capabilities, accelerate market access, and strengthen their presence in high-growth therapeutic areas. Strategic partnerships support critical care drugs by speeding up research, development, and market entry through shared expertise and resources. They enable pharmaceutical companies to collaborate with hospitals, research institutions, or biotech firms to improve drug innovation and clinical trial efficiency. For instance, in March 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical company, partnered with Pharmazz Inc., a US-based pharmaceutical company, to launch and commercialize Centhaquine, an innovative resuscitative drug for hypovolemic shock, in India under the brand name Lyfaquin. This strategic move grants Dr. Reddy’s exclusive marketing and distribution rights in India and Nepal, while Pharmazz will receive upfront payments and royalties. The partnership strengthens Dr. Reddy’s critical care portfolio by introducing a novel therapy approved by the Drugs Controller General of India (DCGI) for emergency conditions, reinforcing its focus on life-saving treatments for critically ill patients.

Who Are The Prominent Global Companies Shaping The Critical Care Drugs Market Landscape?

Major companies operating in the critical care drugs market are Intas Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Ltd., Zydus Lifesciences Limited, Cargus Biopharma, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Mankind Pharma, Novalab Healthcare, Arlak Biotech Ltd., Pax Healthcare, SwissChem Healthcare, Iskon Remedies, Salvus Pharma, Fortune Labs, H&I Critical Care, Biofield Pharma.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/critical-care-drugs-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Critical Care Drugs Market?

North America was the largest region in the critical care drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the critical care drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Critical Care Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27266&type=smp

Browse Through More Reports Similar to the Global Critical Care Drugs Market 2026, By The Business Research Company

Landscaping Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/landscaping-services-global-market-report

Architectural Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/architectural-services-global-market-report

Crop Production Market Report 2026

https://www.thebusinessresearchcompany.com/report/crop-production-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the critical care drugs market from 2025–2034 with trusted insights from The Business Research Company

How Will The Critical Care Drugs Market Valuation Change Between Now And 2029?

The critical care drugs market has experienced substantial growth in recent years. It is anticipated to expand from $1.06 billion in 2024 to $1.13 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.6%. This historical increase can be attributed to various factors, including a rise in ICU admissions, the escalating prevalence of chronic and life-threatening conditions, an increase in surgical interventions, the global aging population, a higher incidence of trauma and accidents, and frequent outbreaks of infectious diseases.

The critical care drugs market size is expected to undergo significant expansion over the next few years, projecting to reach $1.44 billion in 2029, with a compound annual growth rate (CAGR) of 6.2%. This growth during the forecast period is driven by several factors, including the rising prevalence of multi-organ failure, an increasing demand for advanced ICU treatments, a growing geriatric population facing complex health conditions, the expansion of hospital infrastructure in emerging economies, rising incidences of antimicrobial resistance, an enhanced focus on rapid-response emergency care, and increased investments in the development of novel drugs for acute conditions. Major trends anticipated in this period include the development of novel biologics, the integration of AI in ICU drug management, advancements in personalized medicine, improvements in drug delivery systems, the expansion of tele-ICU services, continuous innovation in sepsis and shock treatments, and the incorporation of nanotechnology for improved drug efficacy.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27266&type=smp

What Underlying Factors Are Supporting The Critical Care Drugs Market Growth?

The anticipated increase in surgical operations is expected to drive the expansion of the critical care drugs market moving forward. Surgical procedures are medical interventions where healthcare professionals operate on the body to correct or treat various health issues, including injuries or diseases. The rising incidence of chronic conditions requiring operative treatment is contributing to the increasing number of these surgical procedures. Critical care drugs are utilized during surgeries to manage pain, stabilize vital functions, prevent infections, and aid recovery throughout and after the operation. For instance, in May 2025, information from the Australian Institute of Health and Welfare, an Australia-based government agency, revealed that in 2023–24, approximately 778,500 patients were admitted for surgery from public hospital waiting lists, marking a 5.8% rise compared to 2022–23. Thus, the growing volume of surgical procedures is propelling the growth of the critical care drugs market.

Which Sub-Segments Are Driving Growth Within The Critical Care Drugs Market?

The critical care drugs market covered in this report is segmented

1) By Drug Type: Opioids, Morphine, Pethidine, Naloxone, Fentanyl, Benzodiazepines, Diazepam, Midazolam, Lorazepum, Other Types

2) By Clinical Applications: Sepsis And Septic Shock, Acute Respiratory Distress Syndrome (ARDS), Acute Cardiovascular Events, Acute Kidney Injury, Traumatic Injuries

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Inhalation, Subcutaneous

4) By End User: Intensive Care Unit (ICU), Coronary Care Unit (CCU), Operation Theatres, Trauma Centers

Subsegments:

1) By Opioids: Codeine, Hydromorphone, Oxycodone, Tapentadol, Methadone

2) By Morphine: Immediate-Release Morphine, Extended-Release Morphine, Injectable Morphine, Oral Morphine Solutions

3) By Pethidine: Injectable Pethidine, Oral Pethidine, Pethidine Combinations

4) By Naloxone: Injectable Naloxone, Nasal Naloxone, Auto-injector Naloxone

5) By Fentanyl: Transdermal Patches, Injectable Fentanyl, Buccal Tablets, Sublingual Spray, Lozenges

6) By Benzodiazepines: Short-Acting Benzodiazepines, Intermediate-Acting Benzodiazepines, Long-Acting Benzodiazepines

7) By Diazepam: Oral Tablets, Injectable Diazepam, Rectal Gel, Oral Solution

8) By Midazolam: Injectable Midazolam, Nasal Spray, Buccal Formulation, Oral Syrup

9) By Lorazepam: Oral Tablets, Injectable Lorazepam, Oral Concentrate

10) By Other Types: Propofol, Ketamine, Dexmedetomidine, Etomidate, Clonidine

What Future-Focused Trends Are Anticipated In The Critical Care Drugs Market?

Leading companies active in the critical care drugs market are prioritizing strategic alliances to expand their product ranges, enhance research proficiencies, accelerate entry into markets, and strengthen their presence in high-growth therapeutic areas. Strategic partnerships assist critical care drugs by speeding up research, development, and market accessibility through shared expertise and resources. They enable pharmaceutical firms to collaborate with hospitals, research institutions, or biotech companies to improve drug innovation and the efficiency of clinical trials. For instance, in March 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical company, joined forces with Pharmazz Inc., a US-based pharmaceutical company, to launch and commercialize Centhaquine, an innovative resuscitative drug for hypovolemic shock, in India under the brand name Lyfaquin. This strategic maneuver grants Dr. Reddy’s exclusive marketing and distribution rights in India and Nepal, while Pharmazz will receive upfront payments and royalties. The partnership bolsters Dr. Reddy’s critical care portfolio by introducing a novel therapy approved by the Drugs Controller General of India (DCGI) for emergency conditions, reinforcing its dedication to life-saving treatments for critically ill patients.

Which Companies Hold A Competitive Edge In The 71 Market?

Major companies operating in the critical care drugs market are Intas Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Ltd., Zydus Lifesciences Limited, Cargus Biopharma, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Mankind Pharma, Novalab Healthcare, Arlak Biotech Ltd., Pax Healthcare, SwissChem Healthcare, Iskon Remedies, Salvus Pharma, Fortune Labs, H&I Critical Care, and Biofield Pharma.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/critical-care-drugs-global-market-report

Which Region Dominates The Critical Care Drugs Market Today?

North America was the largest region in the critical care drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the critical care drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27266&type=smp

Browse Through More Reports Similar to the Global Critical Care Drugs Market 2025, By The Business Research Company

Ceiling Tile Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ceiling-tile-global-market-report

Synthetic Gypsum Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/synthetic-gypsum-global-market-report

Laminated Glass Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/laminated-glass-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Critical Care Drugs Market Between 2025 And 2029?

The critical care drugs market size has seen robust expansion in recent years. It is anticipated to expand from $1.06 billion in 2024 to $1.13 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.6%. This growth during the historical period is attributable to several factors, including an increase in ICU admissions, the rising prevalence of chronic and life-threatening illnesses, a greater number of surgical procedures, the aging global population, an uptick in trauma and accident occurrences, and frequent outbreaks of infectious diseases.

The critical care drugs market is projected to observe robust growth in the coming years. It is set to expand to $1.44 billion by 2029, achieving a compound annual growth rate (CAGR) of 6.2%. This anticipated growth is influenced by the rising prevalence of multi-organ failure, increasing demand for advanced ICU treatments, a growing geriatric population with intricate health conditions, the expansion of hospital infrastructure in emerging economies, an uptick in antimicrobial resistance cases, a heightened focus on rapid-response emergency care, and increasing investments in the development of novel drugs for acute conditions. Significant trends during this forecast period include the creation of new biologics, the integration of AI in ICU drug management, advancements in personalized medicine, improvements in drug delivery systems, the expansion of tele-ICU services, continuous innovation in sepsis and shock treatments, and the adoption of nanotechnology for improved drug efficacy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27266&type=smp

Which Drivers Are Impacting The Critical Care Drugs Market?

An increase in surgical operations is anticipated to drive the expansion of the critical care drugs market moving forward. Surgical procedures involve medical interventions performed by physicians to correct or manage health conditions, including injuries or illnesses. The volume of surgical interventions is rising, driven by the increasing occurrence of chronic illnesses necessitating operative care. Critical care drugs are utilized during surgical procedures for pain management, stabilization of vital signs, infection prevention, and to aid recovery both during and following surgery. For example, in May 2025, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that approximately 778,500 patients were admitted for surgery from public hospital waiting lists in 2023–24, which represented a 5.8% rise compared to 2022–23. Consequently, the growing frequency of surgical procedures is fueling the expansion of the critical care drugs market.

How Is The Critical Care Drugs Market Classified Into Different Segments?

The critical care drugs market covered in this report is segmented

1) By Drug Type: Opioids, Morphine, Pethidine, Naloxone, Fentanyl, Benzodiazepines, Diazepam, Midazolam, Lorazepum, Other Types

2) By Clinical Applications: Sepsis And Septic Shock, Acute Respiratory Distress Syndrome (ARDS), Acute Cardiovascular Events, Acute Kidney Injury, Traumatic Injuries

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Inhalation, Subcutaneous

4) By End User: Intensive Care Unit (ICU), Coronary Care Unit (CCU), Operation Theatres, Trauma Centers

Subsegments:

1) By Opioids: Codeine, Hydromorphone, Oxycodone, Tapentadol, Methadone

2) By Morphine: Immediate-Release Morphine, Extended-Release Morphine, Injectable Morphine, Oral Morphine Solutions

3) By Pethidine: Injectable Pethidine, Oral Pethidine, Pethidine Combinations

4) By Naloxone: Injectable Naloxone, Nasal Naloxone, Auto-injector Naloxone

5) By Fentanyl: Transdermal Patches, Injectable Fentanyl, Buccal Tablets, Sublingual Spray, Lozenges

6) By Benzodiazepines: Short-Acting Benzodiazepines, Intermediate-Acting Benzodiazepines, Long-Acting Benzodiazepines

7) By Diazepam: Oral Tablets, Injectable Diazepam, Rectal Gel, Oral Solution

8) By Midazolam: Injectable Midazolam, Nasal Spray, Buccal Formulation, Oral Syrup

9) By Lorazepam: Oral Tablets, Injectable Lorazepam, Oral Concentrate

10) By Other Types: Propofol, Ketamine, Dexmedetomidine, Etomidate, Clonidine

What Are The Major Trends Driving The Growth Of The Critical Care Drugs Market?

Leading companies in the critical care drugs market are concentrating on strategic alliances to expand their product portfolios, enhance research capabilities, accelerate market entry, and solidify their standing in high-growth therapeutic areas. These strategic collaborations support critical care drug advancements by speeding up research, development, and market access through shared knowledge and resources. They facilitate pharmaceutical firms in working with hospitals, research institutions, or biotech companies to boost drug innovation and improve the efficiency of clinical trials. For instance, in March 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical company, formed a partnership with Pharmazz Inc., a US-based pharmaceutical company, to introduce and market Centhaquine, a groundbreaking resuscitative drug for hypovolemic shock, in India under the brand name Lyfaquin. This strategic decision grants Dr. Reddy’s exclusive marketing and distribution rights in India and Nepal, while Pharmazz will receive initial payments and royalties. The partnership bolsters Dr. Reddy’s critical care portfolio by integrating a novel therapy, approved by the Drugs Controller General of India (DCGI) for emergency medical situations, reinforcing its dedication to providing life-saving treatments for critically ill patients.

Who Are The Core Companies Influencing The Critical Care Drugs Market Landscape?

Major companies operating in the critical care drugs market are Intas Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Ltd., Zydus Lifesciences Limited, Cargus Biopharma, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Mankind Pharma, Novalab Healthcare, Arlak Biotech Ltd., Pax Healthcare, SwissChem Healthcare, Iskon Remedies, Salvus Pharma, Fortune Labs, H&I Critical Care, and Biofield Pharma.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/critical-care-drugs-global-market-report

What Are The Key Regional Factors Influencing The Critical Care Drugs Market Growth?

North America was the largest region in the critical care drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the critical care drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Critical Care Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27266&type=smp

Browse Through More Reports Similar to the Global Critical Care Drugs Market 2025, By The Business Research Company

Ceiling Tile Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ceiling-tile-global-market-report

Gypsum Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gypsum-global-market-report

Synthetic Gypsum Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/synthetic-gypsum-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model